

# Timothy W Meyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2254316/publications.pdf>

Version: 2024-02-01

78  
papers

6,943  
citations

81900

39  
h-index

79698

73  
g-index

79  
all docs

79  
docs citations

79  
times ranked

6313  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary Protein Intake and the Progressive Nature of Kidney Disease. New England Journal of Medicine, 1982, 307, 652-659.	27.0	1,863
2	Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation, 2017, 135, 1832-1847.	1.6	462
3	Uremia. New England Journal of Medicine, 2007, 357, 1316-1325.	27.0	403
4	Colonic Contribution to Uremic Solutes. Journal of the American Society of Nephrology: JASN, 2011, 22, 1769-1776.	6.1	340
5	Removal of P-Cresol Sulfate by Hemodialysis. Journal of the American Society of Nephrology: JASN, 2005, 16, 3430-3436.	6.1	239
6	Effect of Increasing Dietary Fiber on Plasma Levels of Colon-Derived Solutes in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1603-1610.	4.5	235
7	Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut Microbiota. Cell Host and Microbe, 2016, 20, 709-715.	11.0	201
8	Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model. Circulation Research, 2015, 117, 720-730.	4.5	197
9	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International, 2014, 85, 1214-1224.	5.2	182
10	Uremic solutes from colon microbes. Kidney International, 2012, 81, 949-954.	5.2	148
11	Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2017, 28, 321-331.	6.1	132
12	Late Consequences of Acute Ischemic Injury to a Solitary Kidney. Journal of the American Society of Nephrology: JASN, 1999, 10, 366-373.	6.1	117
13	Prominent Accumulation in Hemodialysis Patients of Solutes Normally Cleared by Tubular Secretion. Journal of the American Society of Nephrology: JASN, 2014, 25, 615-622.	6.1	115
14	Numerous protein-bound solutes are cleared by the kidney with high efficiency. Kidney International, 2013, 84, 585-590.	5.2	111
15	Increasing the Clearance of Protein-Bound Solutes by Addition of a Sorbent to the Dialysate. Journal of the American Society of Nephrology: JASN, 2007, 18, 868-874.	6.1	104
16	Increasing Dialysate Flow and Dialyzer Mass Transfer Area Coefficient to Increase the Clearance of Protein-bound Solutes. Journal of the American Society of Nephrology: JASN, 2004, 15, 1927-1935.	6.1	100
17	Contribution of Residual Function to Removal of Protein-Bound Solutes in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 290-296.	4.5	91
18	Removal of the Protein-Bound Solutes Indican and P-Cresol Sulfate by Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 85-90.	4.5	86

#	ARTICLE	IF	CITATIONS
19	Tubular Secretion in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2148-2155.	6.1	83
20	New insights into uremic toxicity. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 560-565.	2.0	79
21	Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients. <i>PLoS ONE</i> , 2015, 10, e0143731.	2.5	79
22	Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. <i>Molecular Pharmaceutics</i> , 2016, 13, 3130-3140.	4.6	79
23	Free Levels of Selected Organic Solutes and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) Investigators. <i>PLoS ONE</i> , 2015, 10, e0126048.	2.5	75
24	Characteristics of Colon-Derived Uremic Solutes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1398-1404.	4.5	73
25	Contribution of tubular injury to loss of remnant kidney function. <i>Kidney International</i> , 1998, 54, 1157-1165.	5.2	70
26	Effect of Increasing Dialyzer Mass Transfer Area Coefficient and Dialysate Flow on Clearance of Protein-Bound Solutes: A Pilot Crossover Trial. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1042-1049.	1.9	68
27	An Enlarged Profile of Uremic Solutes. <i>PLoS ONE</i> , 2015, 10, e0135657.	2.5	68
28	Selectively increasing the clearance of protein-bound uremic solutes. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1574-1579.	0.7	67
29	Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. <i>Kidney International</i> , 2017, 92, 1484-1492.	5.2	65
30	The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. <i>Kidney International</i> , 2005, 68, 867-877.	5.2	64
31	Uremic Toxin Clearance and Cardiovascular Toxicities. <i>Toxins</i> , 2018, 10, 226.	3.4	61
32	Protein-Bound Molecules: A Large Family With a Bad Character. <i>Seminars in Nephrology</i> , 2014, 34, 106-117.	1.6	58
33	Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. <i>Kidney International</i> , 2017, 91, 1186-1192.	5.2	55
34	Tubular injury in glomerular disease. <i>Kidney International</i> , 2003, 63, 774-787.	5.2	51
35	Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3469-3478.	6.1	51
36	Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. <i>BMC Nephrology</i> , 2013, 14, 134.	1.8	50

#	ARTICLE	IF	CITATIONS
37	Approaches to Uremia. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2151-2158.	6.1	47
38	Contribution of Angiotensin II to Late Renal Injury after Acute Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1278-1286.	6.1	46
39	Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy. <i>Diabetes</i> , 2018, 67, 2096-2106.	0.6	42
40	Glomerular Injury and Tubular Loss in Adriamycin Nephrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1391-1400.	6.1	40
41	Dialysis Cannot be Dosed. <i>Seminars in Dialysis</i> , 2011, 24, 471-479.	1.3	37
42	Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 70, 48-58.	1.9	33
43	Exercise Promotes Collateral Artery Growth Mediated by Monocytic Nitric Oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1862-1871.	2.4	32
44	Twice-Weekly Hemodialysis Is an Option for Many Patients in Times of Dialysis Unit Stress. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1141-1142.	6.1	32
45	Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1992-1999.	6.1	30
46	Effect of a sustained difference in hemodialytic clearance on the plasma levels of p-cresol sulfate and indoxyl sulfate. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1335-1341.	0.7	29
47	The Effect of Uremic Solutes on the Organic Cation Transporter 2. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2551-2557.	3.3	23
48	Methylamine clearance by haemodialysis is low. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1608-1613.	0.7	19
49	Renal structural abnormalities following recovery from acute puromycin nephrosis. <i>Kidney International</i> , 2002, 62, 496-506.	5.2	16
50	Contribution of "clinically negligible" residual kidney function to clearance of uremic solutes. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 846-853.	0.7	16
51	Effect of Angiotensin II Blockade on Renal Injury in Mineralocorticoid-Salt Hypertension. <i>Hypertension</i> , 2000, 36, 569-574.	2.7	14
52	Coated Carbon Hemoperfusion Provides Limited Clearance of Protein-bound Solutes. <i>Artificial Organs</i> , 2008, 32, 717-724.	1.9	14
53	Metabolomic analysis of uremic pruritus in patients on hemodialysis. <i>PLoS ONE</i> , 2021, 16, e0246765.	2.5	14
54	Intensive Hemodialysis Fails to Reduce Plasma Levels of Uremic Solutes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 361-362.	4.5	13

#	ARTICLE	IF	CITATIONS
55	The incidence and characteristics of purposeful heading in male and female youth football (soccer) within Australia. <i>Journal of Science and Medicine in Sport</i> , 2021, 24, 603-608.	1.3	13
56	Indoxyl Sulfate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 3-4.	4.5	12
57	The Removal of Protein-Bound Solutes by Dialysis. , 2012, 22, 203-206.		11
58	Impaired Tubular Secretion of Organic Solutes in Advanced Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2877-2884.	6.1	10
59	The Effect of the FIFA 11+ with Added Neck Exercises on Maximal Isometric Neck Strength and Peak Head Impact Magnitude During Heading: A Pilot Study. <i>Sports Medicine</i> , 2022, 52, 655-668.	6.5	10
60	Accumulation of uremic solutes in the cerebrospinal fluid in experimental acute renal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F296-F302.	2.7	9
61	The effect of ball characteristics on head acceleration during purposeful heading in male and female youth football players. <i>Science and Medicine in Football</i> , 2021, 5, 1-9.	2.0	7
62	Removal of Uremic Solutes from Dialysate by Activated Carbon. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1168-1175.	4.5	7
63	Barriers to Reducing Hemodialysis Time and Frequency in Patients with Residual Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2112-2116.	6.1	6
64	Free and total p-cresol sulfate levels and infectious hospitalizations in hemodialysis patients in CHOICE and HEMO. <i>Medicine (United States)</i> , 2017, 96, e5799.	1.0	5
65	Improving Clearance for Renal Replacement Therapy. <i>Kidney360</i> , 2021, 2, 1188-1195.	2.1	5
66	More Dialysis Has Not Proven Much Better. <i>Seminars in Dialysis</i> , 2016, 29, 481-490.	1.3	4
67	Why Is the GFR So High?: Implications for the Treatment of Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 980-987.	4.5	4
68	Association of Plasma Uremic Solute Levels with Residual Kidney Function in Children on Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1531-1538.	4.5	3
69	Untargeted mass spectrometry discloses plasma solute levels poorly controlled by hemodialysis. <i>PLoS ONE</i> , 2017, 12, e0188315.	2.5	3
70	Improving Solute Clearances by Hemodialysis. <i>Blood Purification</i> , 2022, 51, 20-31.	1.8	3
71	The Pathophysiology of Uremia. , 2010, , 251-264.		2
72	Manipulating the microbiome. <i>Kidney International</i> , 2017, 91, 274-276.	5.2	2

#	ARTICLE	IF	CITATIONS
73	Plasma pseudouridine levels reflect body size in children on hemodialysis. <i>Pediatric Nephrology</i> , 2020, 35, 305-312.	1.7	2
74	Precision medicine in transplantation and hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, ii31-ii36.	0.7	2
75	The Uremic Syndrome. , 2015, , 83-91.		1
76	The Uremic Syndrome. , 2020, , 199-210.		1
77	Impaired Tubular Secretion of Organic Solutes in Acute Kidney Injury. <i>Kidney360</i> , 2020, 1, 724-730.	2.1	1
78	Glomerular Effects of Age and APOL1. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2901-2903.	6.1	0